^
Association details:
| Biomarker: | RYBP deletion |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DOWN-REGULATION OF RING1 AND YY1 BINDING (RYBP) LEADS TO EPIGENETIC OVEREXPRESSION OF ANTI-APOPTOTIC PROTEIN BCL2 IN MYELODYSPLASTIC SYNDROMES
Published date:
05/12/2022
Excerpt:
The expression of RYBP mRNA and its clinical significance was analyzed in MDS patients. BCL-2 specific inhibitor ABT-199 significantly induces cell apoptosis in RYBP-depleted cells…